Trust Company of Vermont’s Ocular Therapeutix OCUL Stock Holding History

Trust Company of Vermont’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$109K	Buy	8,950 +1,750	+24%	+$21.3K	﹤0.01%	444
2025 Q3	$84.2K	Hold	7,200	–	–	﹤0.01%	480
2025 Q2	$66.8K	Buy	7,200 +1,000	+16%	+$7.83K	﹤0.01%	504
2025 Q1	$45.4K	Hold	6,200	–	–	﹤0.01%	534
2024 Q4	$52.9K	Hold	6,200	–	–	﹤0.01%	521
2024 Q3	$53.9K	Hold	6,200	–	–	﹤0.01%	507
2024 Q2	$42.4K	Buy	6,200 +200	+3%	+$1.24K	﹤0.01%	516
2024 Q1	$54.6K	Hold	6,000	–	–	﹤0.01%	477
2023 Q4	$26.8K	Buy	6,000 +1,000	+20%	+$2.96K	﹤0.01%	513
2023 Q3	$15.7K	Buy	5,000 +1,000	+25%	+$4.09K	﹤0.01%	604
2023 Q2	$20.6K	Hold	4,000	–	–	﹤0.01%	583
2023 Q1	$21.1K	Hold	4,000	–	–	﹤0.01%	595
2022 Q4	$11.2K	Buy	+4,000	New	+$13.2K	﹤0.01%	670

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trust Company of Vermont's OCUL Position: Q4 2025 in Review

Trust Company of Vermont increased its Ocular Therapeutix (OCUL) stake by 24% in Q4 2025, buying an estimated $21.3K and bringing the position to 8,950 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #444.

Trust Company of Vermont first reported a position in OCUL in Q4 2022 and has held it in 13 quarters since. 249 funds tracked by Wall St. Rank hold OCUL as of Q4 2025.

Trust Company of Vermont held 8,950 shares of Ocular Therapeutix worth $109K as of Q4 2025.
Trust Company of Vermont bought 1,750 Ocular Therapeutix shares in Q4 2025, an estimated $21.3K.
Ocular Therapeutix made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #444 holding.
Trust Company of Vermont first reported a position in Ocular Therapeutix in Q4 2022 and has held it in 13 quarters since.
249 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.